Holy Stone Healthcare Co., Ltd.
- Biotech or pharma, therapeutic R&D
Holy Stone Healthcare Co., Ltd. (4194.TW), pioneers in Hyaluronan based delivery systems, is a subsidiary of Holy Stone Enterprise Co., Ltd. (3026.TW). Our proprietary platform enables CD44-mediated site-selective uptake of hyaluronan-drug conjugates to where the drug is needed in a localized tissue. We offer tailored HA polymers to carry poorly water soluble and/or systemic-labile payloads that require localized tissue exposure. Our platform assets covering neurodegeneration, oncology, autoimmune diseases, retinal diseases, and RNA delivery are with proven efficacy in human and animals as illustrated below:
•HylNeuro™ (ND108E) – CNS-targeted delivery across BBB for neurodegeneration.
• HylTargis™ (CA102N) – CD44-targeted delivery for solid tumors
•HylMusa™ (IBD98-M) – Mucosal healing and anti-inflammation in GI tract.
•HylRetinX™ (AMD112) – Oral delivery across BRB for retinal diseases
• HylCaryo™ – HA nanoparticle system for RNA/nucleic acid delivery and releasing
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}